# Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma

> **NCT07744529** · PHASE1,PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, Zhejiang University, School of Medicine** · enrollment: 15 (estimated)

## Conditions studied

- Leptomeningeal Metastasis From Lung Cancer

## Interventions

- **DRUG:** Amivantamab+ systemic/ intrathecal Pemetrexed

## Key facts

- **NCT ID:** NCT07744529
- **Lead sponsor:** Second Affiliated Hospital, Zhejiang University, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-28
- **Primary completion:** 2028-05-28
- **Final completion:** 2028-05-28
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744529, "Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07744529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*